About Sionna
Sionna is a publicly listed company based in Natick (United States) founded in 2019. Small molecule therapeutics for cystic fibrosis are developed. Sionna has raised $293 million across 2 funding rounds from investors including T. Rowe Price, Orbimed and RA Capital. The company has 41 employees. Sionna offers products and services including NBD1 Stabilizers and CFTR Modulators. Its focus areas include Life Sciences, Immunology, Drugs and Fibrosis. Its legal entity is SIONNA THERAPEUTICS, INC. Its competitors include Reneo Pharmaceuticals, Blade Therapeutics and Arcturus Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Sionna was founded in 2019 and is based in Natick, United States, within the biotechnology sector. Small molecule therapies are being developed to address cystic fibrosis by targeting the ΔF508 genetic mutation. Normalization of CFTR function is pursued through programs focused on the NBD1, ICL4, and TMD1 regions. Operations center on advancing these pipeline initiatives for improved efficacy in CF treatment.
- Headquarters Natick, United States
- Employees 41
- Stage Public
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website sionnatx.com
- Social LinkedIn X
- Legal Name Sionna Therapeutics, Inc.
- Net Profit-$75.27 M (USD)-22.01as on Dec 31, 2025
- EBITDA-$88.33 M (USD)-26.4as on Dec 31, 2025
- Total Equity Funding$293M (USD)
in 2 rounds
- Latest Funding Round$182M (USD), Series C
Mar 2024
- InvestorsT. Rowe Price
& 8 more
- Employee Count41
Products & Services of Sionna
Sionna offers a comprehensive portfolio of products and services, including NBD1 Stabilizers and CFTR Modulators.
Small molecules stabilizing CFTR's NBD1 to treat cystic fibrosis mutations
Compounds improving CFTR function synergistically for patient benefits
Funding Insights of Sionna
Sionna has successfully raised a total of $293M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $182 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $293M
- Total Rounds 2
- Last Round Series C β $182M
- First Round $111M
(Apr 2022)
- Investors Count 9
All 2 funding rounds of Sionna with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2024 | $182M | Series C | β | Enavate Sciences | |
| Apr 2022 | $111M | Series B | β | Orbimed |
9 investors in total: 9 institutional.
Investors in Sionna
Sionna has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include T. Rowe Price, Orbimed and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private investment firm focused on multiple sectors | vikingglobal.com | Greenwich, United States | ||
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Sector-agnostic VC investment company investing globally | therisefund.com | San Francisco, United States | ||
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
Drug discovery, development, and market assessment consulting services are provided. | 2022 | enavatesciences.com | United States | |
Research funding and support for cystic fibrosis patients are provided. | 1955 | cff.org | Bethesda, United States | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Diversified asset management services are provided to investors globally. | 1937 | troweprice.com | Baltimore, United States |
Investor details for Sionna
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Sionna
30 people are tracked at Sionna (22 in leadership, 8 in board & advisors); the tracked headcount is 41.
| Name | Role | Group |
|---|---|---|
Andy Chu | VP, Information & Technology | Leadership |
Eric Levesque | Director Of Fp&a | Leadership |
Irene Aquino | Senior Director, Patient Advocacy | Leadership |
Mara Furlow | VP, Global Regulatory Affairs | Leadership |
Mark M. | Co-founder And Vice President Of Medicinal Chemistry At Sionna Therapeutics | Leadership |
Meghan Bagshaw | VP, Programs, Portfolio & Operations | Leadership |
Greg Hurlbut | Co-Founder & SVP, Discovery Research | Leadership |
Mark Munson | Co-Founder & VP, Medicinal Chemistry | Leadership |
Charlotte McKee | Chief Medical Officer | Leadership |
Mike Cloonan | President & CEO | Leadership |
Elena Ridloff | CFO & Head of Corporate Development | Leadership |
Michael Hewitt | VP, Chemistry, Manufacturing & Controls | Leadership |
Vanya Sagar | Chief People Officer | Leadership |
Jessica Hauben | Director Clinical Operations | Leadership |
Jamie Kistner | Senior Director Data Management | Leadership |
James Petersen | Associate Director, Assistant Controller | Leadership |
Erica Iorio | Vice President, Finance & Corporate Controller | Leadership |
George Topalov | Director, Medicinal Chemistry | Leadership |
Juliet Labadorf | Senior Director Of Investor Relations & Corporate Development | Leadership |
Stephen Monahan | Director, Clinical Drug Supply | Leadership |
10 more people are available in the full profile.
Complete people profiles for Sionna
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Sionna
Sionna is a publicly listed company on the NASDAQ with ticker symbol SION in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date07 Feb 2025
- Listed onNASDAQ: SION
- Listed entitySionna Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS8294011080
- Share price$4.38 (-6.61% on the day) · 2026-10-13
- Market capitalisation$198.0M
- EPS (diluted, trailing year)$-2.17
- Volume (last session)790,632
Financials of Sionna
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$75.3M | -$88.3M | |
| 2024 | -$61.7M | -$69.9M | |
| 2023 | -$47.3M | -$49.8M | |
| 2022 | -$40.2M | -$41.2M |
Detailed financial statements for Sionna
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Sionna
4 dated milestones of Sionna across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Sionna is founded.
- Funding First funding round of $111.0M.
- Funding Latest funding round, Series C, of $182.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Sionna
Sionna has 3 listed competitors in our database, 3 of them funded. They include Reneo Pharmaceuticals, Blade Therapeutics and Arcturus Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| reneopharma.com | 2015 | San Diego, United States | $145M | 48 | Small molecule therapies for orphan diseases are being developed. | |
| blademed.com | 2015 | San Francisco, United States | $93M | 30 | Antifibrotic strategies are developed for congenital and acquired fibrotic diseases. | |
| arcturusrx.com | 2013 | San Diego, United States | $1.3M | 337 | RNAi technologies are developed for treating rare orphan diseases. |
Detailed competitors of Sionna
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Sionna
The website of Sionna (sionnatx.com) receives about 6.2K visits a month.
- Monthly visits6.2K
▲ 62.7% vs previous month
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Sionna (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sionna
Complete news archive for Sionna
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sionna
Sionna was founded in 2019 and raised its 1st funding round 3 years after it was founded.
Sionna is headquartered in Natick, United States. It is registered at Natick, Massachusetts, United States.
Sionna is a funded company, having raised a total of $293M across 2 funding rounds to date. The company's 1st funding round was a Series B of $111M, raised on Apr 2022.
Sionna has 41 employees.
Sionna was founded in 2019 and is based in Natick, United States, within the biotechnology sector. Small molecule therapies are being developed to address cystic fibrosis by targeting the ΞF508 genetic mutation. Normalization of CFTR function is pursued through programs focused on the NBD1, ICL4, and TMD1 regions. Operations center on advancing these pipeline initiatives for improved efficacy in CF treatment.
Sionna's top competitors include Arcturus Therapeutics, Reneo Pharmaceuticals and Blade Therapeutics.
Sionna offers NBD1 Stabilizers and CFTR Modulators.
Yes, Sionna is publicly traded on NASDAQ under the ticker symbol SION.
Sionna has 9 investors. Key investors include T. Rowe Price, Orbimed, RA Capital, Cystic Fibrosis Foundation, and Atlas Venture.
Sionna operates through Sionna Therapeutics, Inc..